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Abstract. Contemporary research has focused on the func-
tion of long non-coding RNAs (lncRNAs) in carcinogenesis. 
However, the involvement of the lncRNA, steroid receptor 
RNA activator (SRA), in cervical carcinogenesis remains to 
be elucidated. In the present study, we investigated the bio-
functional consequences of lncRNA SRA knockdown in vitro. 
To verify the role of lncRNA SRA in cell proliferation, migra-
tion, and invasion, lncRNA RNA interference was utilized to 
knock down lncRNA SRA expression in cervical cancer cell 
lines, resulting in our discovery that lncRNA SRA knockdown 
inhibited cell proliferation, cell migration and tumor invasion 
in the cervical cancer cell lines. Additionally, in vitro experi-
ments using the lncRNA SRA-knockdown cervical cancer 
cell lines revealed that lncRNA SRA is a strong inducer and 
modulator of the expression of genes related to epithelial-
mesenchymal transition and the NOTCH signaling pathway. 
In conclusion, our findings demonstrated that lncRNA SRA is 
highly correlated with cancer progression and cervical cancer 
cell proliferation and migration. Furthermore, these results 
indicate that lncRNA SRA may be a potential therapeutic 
target and prognostic marker for cervical malignancy.
Introduction
Cervical cancer is the fourth leading cause of cancer-related 
mortality in women worldwide (1). Widespread employment of 
screening programs has reduced the incidence and mortality 
associated with this cancer. However, it remains a major public 
health issue, particularly concerning advanced cases (1). 
Accordingly, recent research has focused on identifying 
tumor-specific markers capable of predicting the biological 
behavior of cervical cancers with respect to cell motility and 
invasion (2).
Non-coding RNAs (ncRNAs) are potential key factors 
influencing gene regulation and cancer cell phenotypes (3,4). 
Recently, more than 3,000 human long intervening coding 
RNAs and most long ncRNAs (lncRNAs) have been found to 
correlate the activity associated with DNA-binding proteins, 
including chromatin-modifying complexes (5) that epigeneti-
cally modify the expression of various genes (6). Additionally, 
transcription of lncRNAs modulates gene expression in 
response to external oncogenic stimuli or DNA damage (7).
Human lncRNA, steroid receptor RNA activator (SRA), 
was shown to co-activate several human sex hormone recep-
tors and was found to be highly associated with several types 
of cancers including ovarian and breast cancer (8-11). In 
addition, lncRNA SRA functionally interacts with several 
proteins, including nuclear receptors, such as the retinoic acid 
receptor, as well as proteins involved in myogenic differentia-
tion (12,13). Although lncRNA SRA is also correlated with the 
progression of other malignancies, its role in cervical cancer 
has not yet been fully elucidated.
The present study investigated the expression and 
molecular function of SRA in cervical cancer cell lines and 
elucidated the role of SRA in the metastatic progression of 
cervical cancer.
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Materials and methods
Cell lines. Squamous cell cervical carcinoma (SiHa) cells and 
epidermoid cell cervical carcinoma (CaSki; originally derived 
from a small-bowel mesentery metastasis) cells and human 
cervical cancer cell lines [American Type Culture Collection 
(ATCC) manassas, vA, uSA], were maintained in Dulbecco's 
modified Eagle's medium (Gibco-BRL, Gaithersburg, MD, 
uSA) containing 10% (v/v) fetal bovine serum and penicillin/
streptomycin. Cells were maintained at 37̊C in an atmosphere 
of 95% air and 5% CO2. Only cells that had been passaged <20 
times were utilized in the experiments.
Quantitative reverse-transcription polymerase chain reaction 
(qRT-PCR). We extracted total RNA using TRIzol reagent 
(Invitrogen, Carlsbad, CA, uSA) according to the manufac-
turer's instructions. Total RNA (2 µg) was reverse transcribed 
into first-strand cDNA using a reverse transcription reagent kit 
(Invitrogen). The cDNA template was amplified by qRT-PCR 
using the SYBR-Green Real-Time PCR kit (Toyobo Co., Ltd., 
Osaka, Japan) on an ABI StepOnePlus Real-Time PCR system 
(Applied Biosystems, Foster City, CA, USA). We used U6 
as the internal standard for all quantifications. We analyzed 
the relative gene expression using the 2-ΔΔCt method, and the 
results are expressed as the extent of change relative to control 
values. All qRT-PCR experiments were repeated at least three 
times. Primers used for the PCR reactions are listed in Table I.
Small interfering RNA (siRNA) transfection. We obtained 
siRNA for SRA lncRNA and negative-control siRNA (siNC) 
from Genolution Pharmaceuticals (Seoul, Korea). Cells 
(5x104 cells/well) were seeded into 6-well plates and trans-
fected with 10 nm siRNA in phosphate-buffered saline using 
the G-Fectin kit (Genolution Pharmaceuticals) according to 
the manufacturer's instructions. The siRNA-transfected cells 
were used in the in vitro assays 48 h after transfection. The 
target sequence for the siSRA was, 5'-CTCCCTTCTTACC 
ACCACCA-3'. Experiments were repeated at least three times.
Plasmid constructs and generation of stable cell lines. 
Full-length human SRA-transcript cDNA was amplified 
by PCR and inserted into the pLenti6/v5-D-TOPO vector 
using the viraPower lentiviral expression system (Invitrogen) 
according to the manufacturer's instructions. We then trans-
fected the plasmid into 293FT cells for packaging, with the 
resultant lentivirus used to infect the desired cell lines. Stably 
SRA-transfected cells were selected in medium containing 
blasticidin (Invitrogen).
Cell proliferation assay. Cell Counting Kit-8 (CCK-8; Dojindo 
Laboratories, Kumamoto, Japan) was utilized to evaluate cell 
proliferation. Cells (2x103 cells/well) were seeded into 96-well 
flat-bottomed plates containing 100 µl of complete medium 
per well. The cells were incubated overnight to allow for cell 
attachment and recovery, and subsequently transfected with 
siNC or siSRA for 24, 48, 72 or 96 h. An aliquot of 10 µl of 
CCK-8 solution was supplemented into each well, followed by 
incubation for 2 h. Absorbance was measured at 450 nm to 
estimate the number of viable cells in each well. The assay was 
performed in triplicate.
Matrigel invasion assay. We performed a matrigel inva-
sion assay using the BD Biocoat Matrigel invasion chamber 
(pore size, 8-µm; 24-wells; BD Biosciences, Bedford, MA, 
uSA) according to the manufacturer's protocol. Cells (5x104) 
were seeded in the upper chamber, which contained serum-
free medium, and complete medium was added to the lower 
chamber. The matrigel-invasion chamber was incubated at 
37̊C under 5% CO2 for 48 h. Non-invading cells were removed 
from the upper chamber using cotton-tipped swabs. Cells that 
had invaded through the pores onto the lower side of the filter 
were stained (Diff-Quik; Sysmex, Kobe, Japan) and counted 
Table I. Primer sequences used in the present study.
 Primer sequence
 ---------------------------------------------------------------------------------------------------------------------------------------------------------
Gene Forward (5'-3') Reverse (5'-3') Product size (bp)
SRA CTCCCTTCTTACCACCACCA TGCAGATACACAGGGAGCAG 217
mmP-9 CGCTACCACCTCGAACTTTG GCCATTCACGTCGTCCTTAT 196
mmP-2 GGATGATGCCTTTGCTCG ATAGGATGTGCCCTGGAA 487
vEGF TTGCTGCTCTACCTCCAC AAATGCTTTCTCCGCTCT 419
E-cadherin ATTCTGATTCTGCTGCTCTTG AGTAGTCATAGTCCTGGTCCT 421
β-catenin TGCAGTTCGCCTTCACTATG ACTAGTCGTGGAATGGCACC 162
N-cadherin CCCAAGACAAAGAGACCCAG GCCACTGTGCTTACTGAATTG 140
vimentin TGGATTCACTCCCTCTGGTT GGTCATCGTGATGCTGAGAA 111
Snail GAGGCGGTGGCAGACTAG GACACATCGGTCAGACCAG 178
NOTCH1 GCCGCCTTTGTGCTTCTGTTC CCGGTGGTCTGTCTGGTCGTC 300
HES1 TCAACACGACACCGGATAAA TCAGCTGGCTCAGACTTTCA 111
P300 GACCCTCAGCTTTTAGGAATCC TGCCGTAGCAACACAGTGTCT 301
SRA, steroid receptor RNA activator; mmP, matrix metalloproteinase; vEGF, vascular endothelial growth factor.
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using a hemocytometer. The assay was repeated at least three 
times.
Wound-healing migration assay. We evaluated cell migration 
using a wound-healing assay. Approximately 5x105 cells were 
seeded into 6-well culture plates containing serum-enriched 
medium and allowed to grow to 90% confluence in complete 
medium. The serum-containing medium was eliminated, and 
cells were serum-starved for 24 h. When the cells reached 
100% confluence, an artificial homogenous wound was made 
by scratching the monolayer using a sterile 200-µl pipette tip. 
Following the scratching, cells were washed with serum-free 
medium. Images of cells migrating into the wound were 
captured at 0, 24 and 48 h using a microscope. Three indepen-
dent experiments were performed in triplicate.
Western blot analysis. We used radioimmunoprecipitation 
assay buffer to extract proteins, and a Pierce BCA protein assay 
kit (both from Thermo Fisher Scientific, Waltham, MA, USA) 
was used to measure protein concentration. Proteins were 
boiled with 2X sample buffer, subsequently resolved on 10% 
sodium dodecyl sulfate-polyacrylamide gels, and transferred 
electrophoretically to polyvinylidene difluoride membranes 
(Millipore, Billerica, MA, USA). After blocking with 5% 
non-fat dried milk in 1X Tris-buffered saline containing 0.1% 
Tween-20 (pH 7.6) at room temperature for 1 h, the membranes 
were incubated with primary antibodies at 4̊C overnight 
under continual agitation. The following primary antibodies 
were used: rabbit anti-human vascular endothelial growth 
factor (vEGF) (1:500), rabbit anti-human matrix metallopro-
teinase (mmP)-2 (1:500) (both from Abcam, Cambridge, uK, 
uSA), rabbit anti-human mmP-9 (1:1,000), rabbit anti-human 
E-cadherin (1:1,000), rabbit anti-human β-catenin (1:1,000) (all 
from Cell Signaling Technology, Danvers, mA, uSA), mouse 
anti-human vimentin (1:1,000; Sigma-Aldrich, St. Louis, mO, 
uSA), mouse anti-human Snail (1:1,000), rabbit anti-human 
SOX-2 (1:1,000), rabbit anti-human Nanog (1:1,000), rabbit anti-
human Oct4 (1:1,000) (all from Cell Signaling Technology), 
and mouse anti-human β-actin (1:5,000; Sigma-Aldrich). We 
visualized the proteins using an enhanced chemiluminescence 
system (Amersham, Little Chalfont, uK), and band intensi-
ties were quantified using a luminescent image analyzer 
(LAS-4000 Mini; Fujifilm, Uppsala, Sweden).
Statistical analysis. IBM SPSS version 23 for Windows 
(SPSS, Inc., Chicago, IL, uSA) was used for statistical 
analysis. The Kolmogorov-Smirnov test was used to validate 
standard normal-distributional assumptions. Statistical signifi-
cance was determined using the Fisher's exact-test, Pearson's 
Chi-square test and Student's t-test. mean differences were 
considered significant at P<0.05. Results are presented as the 
means ± standard deviation.
Results
SRA expression is elevated in cervical cancer cells. We 
performed qRT-PCR to estimate the expression levels of 
SRA in five different cell lines, one of which was derived 
from human embryonic kidney cells (HEK293), whereas the 
other four were derived from human cervical cancers. We 
observed that SRA expression levels were significantly higher 
in epithelioid cervical carcinoma (HeLa), CaSki and SiHa 
cells as compared with levels observed in epidermoid cervical 
carcinoma cells (mE-180) (Fig. 1).
Knockdown of SRA decreases cell proliferation in cervical 
cancer cells. To examine the functional role of SRA in 
cervical cancer cells, siRNA was utilized to downregulate 
SRA expression in the CaSki and SiHa cells, which showed 
significantly higher levels of SRA expression. We evaluated 
the knockdown efficiency of siSRAs, and verified that siSRA 
transfection was more efficient in silencing SRA as compared 
with siNC (Fig. 2A and C). We then performed a CCK-8 assay 
to determine the effect of SRA knockdown on cell prolifera-
tion. Our results showed that siRNA-mediated knockdown of 
SRA in CaSki and SiHa cells substantially decreased cell 
proliferation (Fig. 2B and D). These findings indicated that 
SRA is involved in the proliferation of cervical cancer cells.
SRA knockdown inhibits cervical cancer cell migration 
and invasion. Wound-healing and matrigel-invasion assays 
were performed to determine whether SRA plays a role in 
cervical cancer cell migration and invasion. In the wound-
healing assay, siRNA-mediated knockdown of SRA inhibited 
cell migration in the CaSki and SiHa cells (Fig. 3A and D). 
moreover, SRA-knockdown inhibited cell invasion in the 
CaSki and SiHa cells according to the results of the matrigel-
invasion assay (Fig. 3B and E). The extent of inhibition upon 
SRA knockdown was quantified by qRT-PCR (Fig. 3C and F).
SRA knockdown inhibits MMP-9, MMP-2 and VEGF expres-
sion in cervical cancer cells. To elucidate the molecular 
mechanisms underlying the inhibitory effect of SRA 
knockdown on cell migration and invasion, we explored the 
relationship between SRA expression and mmP-2, mmP-9 
and vEGF expression. We observed that siSRA treatment 
decreased levels of MMP-2, MMP-9 and VEGF mRNA in 
the CaSki cells (Fig. 4A) as well as mmP-2, mmP-9 and 
Figure 1. SRA expression in various cell lines. SRA lncRNA expression was 
evaluated by qRT-PCR, with U6 as an internal control. *P<0.05 vs. non-tumor 
control. lncRNA, long non-coding RNA; qRT-PCR, quantitative reverse tran-
scription polymerase chain reaction; SRA, steroid receptor RNA activator.
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VEGF protein levels (Fig. 4B). These findings indicated that 
SRA promoted cervical cancer cell migration and invasion via 
upregulation of mmP-9, mmP-2 and vEGF expression.
SRA knockdown downregulates expression of genes related to 
epithelial-mesenchymal transition (EMT) and the NOTCH-
signaling pathway in cervical cancer cells. Since EmT is 
crucial to cell migration and invasion, we examined whether 
SRA is required for EmT. EmT was monitored using qRT-PCR 
and western blotting following siRNA-mediated knockdown 
of SRA in CaSki cells. SRA knockdown resulted in increased 
E-cadherin expression and decreased β-catenin and vimentin 
expression (Fig. 5A and B). Additionally, the EMT-mediating 
transcription factor Snail and Twist were downregulated in the 
siSRA-transfected cells relative to levels observed in the siNC-
transfected cells (Fig. 5A and B). These results suggested that 
SRA may be involved in the dysregulation of EmT-related 
genes in cervical cancer cells, thereby promoting migration 
and invasion.
To elucidate the mechanism by which SRA promotes a 
malignant phenotype in cervical cancer cells, we assessed the 
status of important signaling cascades controlled by NOTCH 
in the SRA-knockdown cells. SRA knockdown in the CaSki 
cells resulted in downregulation of NOTCH1, HES1 and p300 
expression [both mRNA (Fig. 6A) and protein (Fig. 6B)]. These 
data indicated that SRA promoted tumor growth in vitro via 
the EmT and NOTCH signaling pathways.
Discussion
lncRNAs are transcripts of >200 nucleotides lacking protein-
coding capability (7). Numerous lncRNAs are capped, spliced 
and polyadenylated similar to their protein-coding coun-
terparts and exhibit tissue-specific expression patterns (14). 
Furthermore, lncRNAs are essential for the regulation of chro-
matin structure, gene expression and translational control (15). 
The mounting list of functionally characterized lncRNAs 
implies that these transcripts are critical to various physi-
ological processes (16). Therefore, these findings suggest that 
modified lncRNA expression may affect cancer development 
and progression (17). However, little is known concerning the 
regulatory roles of lncRNAs and their relevance to malignant 
diseases.
Recently, lncRNAs have become the focus of intense 
research due to their critical roles in malignant processes, 
including tumorigenesis, drug resistance and metas-
tasis (18-20). The present study explored the molecular 
function of SRA expression in cervical cancer cell lines. Our 
findings showed that downregulated SRA expression was 
correlated with decreased cell growth, migration and invasion 
Figure 2. SRA knockdown inhibits the proliferation of cervical cancer cells. (A and C) Cells were transfected with SRA-specific siRNA (siSRA) and negative-
control siRNA (siNC), and knockdown efficiency was determined by qRT-PCR analysis in CaSki and SiHa cells. (B and D) The proliferation capacity of 
cervical cancer cells transfected with siSRA and siNC was determined using the Cell Counting Kit-8 assay. Bars indicate means ± standard deviation of three 
independent experiments; *P<0.05 vs. siNC. CaSki, epidermoid cell cervical carcinoma cells; qRT-PCR, quantitative reverse transcription polymerase chain 
reaction; SiHa, squamous cell cervical carcinoma cells; SRA, steroid receptor RNA activator.
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in cervical cancer cells. This effect of SRA on tumor progres-
sion may be mediated by genes involved in cell migration, 
invasion, EmT and the NOTCH signaling pathway, as well 
as genes that encode vEGF, mmP-9, mmP-2, E-cadherin, 
β-catenin, vimentin, Snail, NOTCH1, p300 and HES1. Our 
findings suggested that SRA could potentially represent a 
novel biomarker and therapeutic target for cervical cancer.
We discovered that knockout of lncRNA SRA expres-
sion decreased cervical cancer cell proliferation, migration 
and invasion. Specifically, the expression levels of MMP-2, 
mmP-9 and vEGF were significantly lower in cells with 
siRNA-mediated SRA knockdown. mmP-2 and mmP-9 
degrade basement-membrane collagen at the site of local inva-
sion, thereby promoting tumor-cell invasion and metastasis, 
which in turn leads to decreased survival rates in various 
types of cancers (21,22). moreover, tumor angiogenesis plays 
a decisive role in tumor growth, invasion and metastasis (23), 
and the angiogenic factor, vEGF, a major target of many anti-
cancer medications, plays a pivotal role in tumor angiogenesis 
and increases the ability of malignant cells to migrate and 
invade Matrigel membranes (24). Our findings suggested that 
SRA stimulated oncogenic activity in cervical cancer cells 
Figure 3. SRA lncRNA promotes cell migration and invasion. (A and D) Wound-healing assay was used to determine migration ability of the siSRA-
transfected CaSki and SiHa cells (magnification, x200). (B and E) Matrigel-invasion assay was used to determine invasion after 24 h in siSRA-transfected 
CaSki and SiHa cells. Each assay was performed in triplicate. Data are presented as means ± standard deviation. (C and F) siRNA-mediated knockdown of 
SRA in CaSki and SiHa cells analyzed using qRT-PCR; *P<0.05 vs. control. CaSki, epidermoid cell cervical carcinoma cells; qRT-PCR, quantitative reverse 
transcription polymerase chain reaction; SiHa, squamous cell cervical carcinoma cells; siSRA, SRA-specific siRNA; SRA, steroid receptor RNA activator.
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by promoting aggressive and metastatic characteristics via 
upregulating mmP-2, mmP-9 and vEGF expression.
We found that knockout of lncRNA SRA in cervical 
cancer cells reduced cell migration and invasion, possibly 
by preventing EmT induction. We analyzed the following 
EmT-related genes in the present study: E-cadherin, 
β-catenin, vimentin, N-cadherin, Snail and Twist. EmT is a 
well-characterized process by which epithelial cells lose their 
cell polarity and cell-to-cell adhesion and acquire migra-
tory and invasive properties to become mesenchymal stem 
cells (25), processes that occur during metastasis in many 
carcinomas (25). Loss of E-cadherin is considered a crucial 
event in EmT, whereas N-cadherin promotes transendothelial 
migration, which causes diminished intercellular connection 
between two adjacent endothelial, thereby allowing cancer 
cells to slip through (26). Additionally, β-catenin weakens 
Figure 4. SRA knockdown decreases mmP-9, mmP-2 and vEGF expression in cervical cancer cells. (A) VEGF, MMP-2 and MMP-9 mRNA expression 
levels were analyzed by qRT-PCR. (B) Protein lysates were obtained from siSRA- and siNC-transfected CaSki cells 48-h post-transfection. VEGF, MMP-2, 
and mmP-9 protein levels were analyzed by western blotting; *P<0.05 vs. siNC. mmP, matrix metalloproteinase; qRT-PCR, quantitative reverse transcription 
polymerase chain reaction; siNC, negative-control siRNA; siSRA, SRA-specific siRNA; SRA, steroid receptor RNA activator; VEGF, vascular endothelial 
growth factor.
Figure 5. Effect of SRA knockdown on EmT-related genes in CaSki cells. CaSki cells were transfected with siSRA and siNC for 48 h. E-cadherin, β-catenin, 
vimentin, N-cadherin, Snail and Twist mRNA expression and protein levels were analyzed by (A) qRT-PCR and (B) western blotting, respectively; *P<0.05 vs. 
siNC. CaSki, epidermoid cell cervical carcinoma cells; EmT, endothelial-to-mesenchymal transition; qRT-PCR, quantitative reverse transcription polymerase 
chain reaction; siNC, negative-control siRNA; siSRA, SRA-specific siRNA; SRA, steroid receptor RNA activator.
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cell-to-cell adhesion between epithelial cells, and promotes 
a more mobile and loosely associated mesenchymal pheno-
type (27). Furthermore, enhanced expression of transcription 
factors, such as Snail and Twist, is associated with loss of 
intercellular adhesion (28), and vimentin constitutes a major 
component of the cytoskeleton in mesenchymal cells, with its 
upregulation promoting EmT induction (29).
In the present study, we also investigated whether the 
NOTCH signaling pathway was compromised upon SRA 
knockdown. A clear relationship was detected between 
decreased levels of NOTCH1, HES1 and p300 proteins and 
SRA knockdown in CaSki cells. The NOTCH signaling 
pathway represents a highly conserved cell-signaling mecha-
nism (30) that contributes to tumor progression, including 
invasion, metastasis, EmT and angiogenesis (31,32). NOTCH1 
is a regulatory transmembrane receptor that plays a crucial 
developmental role in cell-fate determination and pattern 
formation (30). Several studies reported that NOTCH1 
induces anoikis resistance, inhibits p53 activity, upregulates 
myc expression, and abrogates the growth-inhibitory effects 
of TGF-β in cervical cancer cells (33-35). Additionally, HES1 
influences the maintenance of stem and progenitor cells as a 
member of the NOTCH-signaling pathway (36) and p300, a 
transcriptional co-activator in the NOTCH1 pathway, func-
tions as a histone acetyltransferase and regulates transcription 
via chromatin remodeling. Furthermore, p300 also plays a 
crucial role in cell proliferation and differentiation (37).
Based on our results, we hypothesized that lncRNA SRA 
functions as a key regulator of various signaling mechanisms 
involved in EmT establishment and NOTCH signaling. Our 
data provide evidence, for the first time, that lncRNA SRA 
promotes EmT and NOTCH signaling in cervical cancer 
cells, potentially contributing to cervical cancer growth, 
invasion and migration. The clinical impact of lncRNA SRA 
expression and its potential therapeutic value in the treatment 
of advanced cervical cancer patients needs to be evaluated in 
future studies.
In conclusion, these findings showed that lncRNA SRA is 
correlated with motility and invasiveness in cervical cancer 
cells. Furthermore, lncRNA SRA promoted cervical cancer 
progression by inducing cell migration and invasion via upreg-
ulation of mmP-2, mmP-9, vEGF, as well as genes related to 
EmT and the NOTCH signaling pathway. Therefore, lncRNA 
SRA constitutes a potential therapeutic target and prognostic 
marker for cervical cancer.
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